Amarin Corporation PLC

485 articles about Amarin Corporation PLC

• Amarin to Present at the 2023 Cantor Global Healthcare Conference

  9/12/2023

  Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare Conference.

• Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

  8/9/2023

  Amarin Corporation plc announced pricing and reimbursement updates for VAZKEPA in the Netherlands and Italy.

• Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

  8/8/2023

  Amarin Corporation plc (NASDAQ:AMRN) and Neopharm Israel announced today that the two companies have entered into an exclusive marketing and commercialization agreement for VAZKEPA® (icosapent ethyl) in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority.

• Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

  8/7/2023

  The acceptance of icosapent ethyl, an innovative active substance comprising a highly purified omega-3 fatty acid (eicosapentaenoic acid greater or equal to 96%), will provide healthcare professionals in Scotland with an additional treatment option to be considered for eligible patients who are at high risk of a subsequent CV event, such as a second heart attack or stroke.

• Amarin Reports Second Quarter 2023 Financial Results

  8/2/2023

  Amarin Corporation plc (NASDAQ:AMRN) today announced financial results for the quarter ended June 30, 2023 and provided an update on company operations.

• Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

  7/31/2023

  Amarin Corporation plc and Lotus Pharmaceuticals announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA® across 10 countries, including nine in Southeast Asia and South Korea.

• Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

  7/26/2023

  Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.

• Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

  7/25/2023

  Amarin Corporation plc (NASDAQ:AMRN) today announces that following the most recent meeting of the Spanish Drug Pricing Committee (Comisión Interministerial de Precios de los Medicamentos) on July 24, 2023, the Committee is recommending the national reimbursement of VAZKEPA® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular risk.

• Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

  7/20/2023

  Today the Board of Directors of Amarin Corporation plc (NASDAQ: AMRN) announced details regarding the compensation program for the Company’s new President and Chief Executive Officer (CEO), Patrick Holt, who was appointed to the role on July 18, 2023.

• Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally

  7/18/2023

  Amarin Corporation plc announced that it has initiated an organizational restructuring program to right-size and strengthen the Company to enhance shareholder value.

• Amarin Appoints Patrick Holt as President and Chief Executive Officer

  7/18/2023

  Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately.

• Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)

  6/21/2023

  Amarin Corporation plc (NASDAQ:AMRN) and its commercialization partner Biologix FZco, today announced that the Kingdom of Saudi Arabia’s (KSA) Saudi Food and Drug Authority (SFDA) has approved a new indication and label expansion for VASCEPA® (icosapent ethyl) capsules.

• Amarin to Present at Two Upcoming June 2023 Investor Conferences

  6/1/2023

  Amarin Corporation plc announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer and Tom Reilly, Amarin’s Chief Financial Officer, will present at two upcoming investor conferences.

• Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China

  6/1/2023

  Amarin Corporation plc announced that its commercial partner in China, EddingPharm, has received regulatory approval for VASCEPA® from China’s National Medical Products Administration.

• Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

  5/12/2023

  Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

• Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

  5/3/2023

  Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2023 and provided an update on the Company’s operations.

• Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

  4/19/2023

  Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin’s senior management team to discuss the Company’s first quarter 2023 financial results on Wednesday, May 3rd, 2023 at 8:00 a.m. ET.

• Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

  4/17/2023

  Amarin Corporation plc announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer.

• Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

  4/4/2023

  Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel’s Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to VAZKEPA (icosapent ethyl).

• Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

  3/6/2023

  Amarin Corporation plc highlighted new in vitro data supporting the potential mechanistic effects of eicosapentaenoic acid in reducing cardiovascular events in at-risk patients presented at the joint ACC.23 together with the World Congress of Cardiology in New Orleans, LA, March 4-6, 2023.